← Oncology Approval Tracker

FDA DECISION ·

Keytruda + trastuzumab + chemotherapy

pembrolizumab + trastuzumab + fluoropyrimidine- and platinum-containing chemotherapy · Merck

Accelerated approvalIndication revisionGastroesophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

This revised first-line accelerated approval for unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma required PD-L1 expression with a combined positive score of at least 1 on an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The FDA narrowed the prior HER2-positive indication to a PD-L1-defined population.

What research teams should watch

Apply the PD-L1 combined positive score to the correct historical label date and document both HER2 and PD-L1 results.

PRIMARY RECORDS

Sources